| Stephen A Holve, MD | |
|
167 North Main Street, Tuba City, AZ 86045-0600 | |
| (928) 283-2501 | |
| (928) 283-2677 |
| Full Name | Stephen A Holve |
|---|---|
| Gender | Male |
| Speciality | Pediatrics |
| Location | 167 North Main Street, Tuba City, Arizona |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255365763 | NPI | - | NPPES |
| 418485 | Medicaid | AZ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | GFE56401 (California) | Primary |
| Entity Name | Tuba City Regional Health Care Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548294424 PECOS PAC ID: 4284542531 Enrollment ID: O20031105000107 |
News Archive
Weekly Digest (http://www.bullmarket.com/digest), a free investment research publication, announced the publication of a special report on investment opportunities in connection with the H1N1 "Swine Flu" Outbreak, including updated outlooks for GlaxoSmithKline, Sanofi-Aventis, Novartis, Baxter International, Roche Holding and several others.
The authors note that there is a consensus "that the current shortage of primary care physicians will worsen over the next ten years as the nation's population grows and ages and as insurance coverage expands as a result of the Affordable Care Act." They examine whether workplace changes will impact that assessment.
Forest Laboratories, Inc. (NYSE: FRX) and Glenmark Pharmaceuticals S.A. (Switzerland), a wholly owned subsidiary of Glenmark Pharmaceuticals India (GPL) today announced top-line results from a Phase IIb dose range-finding study of oglemilast in patients with Chronic Obstructive Pulmonary Disease (COPD). Once-daily treatment with oglemilast did not show a statistically meaningful increase from baseline compared to placebo in the primary endpoint trough FEV1, a measure of pulmonary function that is decreased in patients with COPD. Oglemilast was well tolerated at all doses studied.
Researchers from the University of California, Irvine and Harvard University have discovered how the Clostridium difficile toxin B recognizes the human Frizzled protein, the receptor it uses to invade intestinal cells and lead to deadly gastrointestinal infections.
Investigators at Stanford University have found a surprising link between creative problem-solving and heightened activity in the cerebellum, a structure located in the back of the brain and more typically thought of as the body's movement-coordination center.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Stephen A Holve, MD Po Box 600, 167 North Main Street, Tuba City, AZ 86045-0600 Ph: (928) 283-2501 | Stephen A Holve, MD 167 North Main Street, Tuba City, AZ 86045-0600 Ph: (928) 283-2501 |
News Archive
Weekly Digest (http://www.bullmarket.com/digest), a free investment research publication, announced the publication of a special report on investment opportunities in connection with the H1N1 "Swine Flu" Outbreak, including updated outlooks for GlaxoSmithKline, Sanofi-Aventis, Novartis, Baxter International, Roche Holding and several others.
The authors note that there is a consensus "that the current shortage of primary care physicians will worsen over the next ten years as the nation's population grows and ages and as insurance coverage expands as a result of the Affordable Care Act." They examine whether workplace changes will impact that assessment.
Forest Laboratories, Inc. (NYSE: FRX) and Glenmark Pharmaceuticals S.A. (Switzerland), a wholly owned subsidiary of Glenmark Pharmaceuticals India (GPL) today announced top-line results from a Phase IIb dose range-finding study of oglemilast in patients with Chronic Obstructive Pulmonary Disease (COPD). Once-daily treatment with oglemilast did not show a statistically meaningful increase from baseline compared to placebo in the primary endpoint trough FEV1, a measure of pulmonary function that is decreased in patients with COPD. Oglemilast was well tolerated at all doses studied.
Researchers from the University of California, Irvine and Harvard University have discovered how the Clostridium difficile toxin B recognizes the human Frizzled protein, the receptor it uses to invade intestinal cells and lead to deadly gastrointestinal infections.
Investigators at Stanford University have found a surprising link between creative problem-solving and heightened activity in the cerebellum, a structure located in the back of the brain and more typically thought of as the body's movement-coordination center.
› Verified 8 days ago
Julianne Alice Ivy, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 167 North Main Street, Tuba City, AZ 86045 Phone: 928-283-2679 | |
Teresa Caya, MD Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 167 N Main Street, Tuba City, AZ 86045 Phone: 866-976-5941 | |
Catherine Ann Golski, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 167 N. Main Street, Tuba City Regional Health Care Corporation, Tuba City, AZ 86045 Phone: 928-283-2501 Fax: 928-283-2677 | |
William H Orman, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 167 North Main Street, Tuba City, AZ 86045 Phone: 928-283-2501 Fax: 928-283-2677 | |
Diana Chi-hwa Hu, MD Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 167 North Main Street, Tuba City, AZ 86045 Phone: 928-283-2501 Fax: 928-283-2677 | |
Jane A Oski, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 167 North Main Street, Tuba City, AZ 86045 Phone: 928-283-2501 Fax: 928-283-2677 |